Roivant Sciences Ltd.
HealthcareNASDAQ:ROIV · NASDAQ Global Market
+$0.57 today
Vol 5.27M · Avg 5.63M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$397.9M -11.5% | -$356.7M -108.4% | $4.2B +479.3% | -$1.1B -20.7% | -$924.1M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.3M -76.2% | $14.1M -36.1% | $22.0M +16.9% | $18.9M +217.9% | $5.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $346.2M +19.8% | $289.0M +44.8% | $199.6M -8.3% | $217.8M -61.5% | $565.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$621.8M -707.0% | -$77.0M -504.8% | $19.0M +200.0% | $6.3M -59.6% | $15.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$770.2M | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.4M +118.8% | -$18.2M -180.1% | $22.7M +420.4% | $4.4M -71.7% | $15.4M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $145.0M +346.3% | -$58.9M -1513.5% | -$3.6M -283.7% | $2.0M +528.5% | $316.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$80.2M +88.7% | -$708.8M +86.5% | -$5.2B -18105.2% | $29.1M +108.5% | -$340.2M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$750.3M +10.6% | -$839.5M -9.7% | -$765.3M +9.3% | -$843.4M -24.4% | -$677.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$8.2M -78.5% | -$4.6M -232.8% | -$1.4M +89.1% | -$12.7M +27.2% | -$17.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $229.4M +720.2% | -$37.0M -134.3% | $107.9M +276651.3% | -$39.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$4.1B | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | -$37.5M -101.9% | $2.0B | $0 | $0 -100.0% | $320.2M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$636.6M -676.3% | $110.5M -97.9% | $5.2B +3859.5% | -$139.4M -23339.0% | $600.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$682.3M +61.4% | -$1.8B -133.9% | $5.2B +11854.6% | -$44.3M -114.6% | $303.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$52.8M -71.8% | -$30.7M -123.7% | $129.8M +776.1% | $14.8M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $463.1M +310.6% | $112.8M -74.3% | $438.6M +15.5% | $379.7M | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$319.5M +75.3% | -$1.3B | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 +100.0% | -$6.0M | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$9.4M -169.9% | $13.4M -23.4% | $17.5M +275.1% | -$10.0M -103.4% | $292.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $134.2M +111.0% | -$1.2B -390.9% | $419.4M -16.0% | $499.5M +62.8% | $306.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $3.8M +404.3% | $747.0K +21.3% | $616.0K -90.2% | $6.3M | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$1.3B +66.2% | -$3.8B -178.7% | $4.9B +1372.1% | -$381.9M -464.6% | -$67.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$758.6M +10.1% | -$844.0M -10.1% | -$766.6M +10.4% | -$856.1M -23.1% | -$695.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.72B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$20.03B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.64B
Ascendis Pharma A/S
NASDAQ:ASND
$13.67B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.17B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.17B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.82B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
SEC Filings
Recent regulatory filings
No filings found.
Does ROIV generate free cash flow?
Roivant Sciences Ltd. (ROIV) generated -$758,558,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does ROIV produce?
Operating cash flow was -$750,349,000.00, before capital expenditures of $8.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.